Voyager Therapeutics (STU:VT6) EBIT: €-109.57 Mil (TTM As of Mar. 2026)


STU:VT6 Voyager Therapeutics Inc STU:VT6
55 GF Score
Price €3.22
GF Value €1.52
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics EBIT?

Voyager Therapeutics STU:VT6 55 EBIT is €-109.57 Mil as of Mar. 2026. GuruFocus rates STU:VT6 with a GF Score™ of 55/100 and a GF Value™ of €1.52 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Voyager Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-26.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-109.57 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Voyager Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -160.74%. Voyager Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -300.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Voyager Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -107.33%.

Voyager Therapeutics  (STU:VT6) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Voyager Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-104.736 * ( 1 - 0% )/( (58.17 + 72.148)/ 2 )
=-104.736/65.159
=-160.74 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=215.448 - 6.849 - ( 167.766 - max(0, 22.666 - 173.095+167.766))
=58.17

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=189.716 - 5.526 - ( 122.379 - max(0, 15.097 - 127.139+122.379))
=72.148

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Voyager Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-104.736/( ( (35.538 + max(-11.627, 0)) + (34.104 + max(-4.099, 0)) )/ 2 )
=-104.736/( ( 35.538 + 34.104 )/ 2 )
=-104.736/34.821
=-300.78 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.504 + 0 + 2.84) - (6.849 + 1.358 + 7.764)
=-11.627

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.292 + 0 + 3.337) - (5.526 + 0.342 + 2.86)
=-4.099

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Voyager Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-109.566/102.084
=-107.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics EBIT Related Terms

Voyager Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics EBIT Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.15 -47.99 111.89 -79.54 -112.60

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.09 -31.75 -26.07 -25.56 -26.18

STU:VT6 vs CRBU, OBIO, WHWK: EBIT Comparison

For the Biotechnology subindustry, Voyager Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's EV-to-EBIT falls into.


STU:VT6
55GF Score
Voyager Therapeutics Inc STU:VT6
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-109.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-109.57 Mil mean?
Voyager Therapeutics (STU:VT6) has a EBIT of €-109.57 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Voyager Therapeutics.
Is Voyager Therapeutics' EBIT too high?
Voyager Therapeutics' current EBIT is €-109.57 Mil. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' EBIT compare to CRBU and OBIO?
Voyager Therapeutics' EBIT of €-109.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Voyager Therapeutics. Voyager Therapeutics's current EBIT is €-109.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (STU:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €3.22 — trading 112.1% above its estimated fair value. The current EBIT is €-109.57 Mil. Voyager Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Voyager Therapeutics (STU:VT6), the current EBIT is €-109.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (STU:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.22 is trading 112.1% above its estimated GF Value™ of €1.52. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:VT6:

  • EBIT: €-109.57 Mil
  • GF Value™: €1.52 vs. price of €3.22 (112.1% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the STU:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score

Get the complete analysis for STU:VT6

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price
€1.52
GF Value